TG40.F Oxurion NV

Healthcare Biotechnology Frankfurt Exchange
0.0002 EUR
Close of Nov 12, 2026
0.0002 0.0086
Market cap
EUR 46.4K
P/E
0.0x
P/B
5.73x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is TG40.F undervalued?

Graham number

The Graham number of Oxurion NV cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oxurion NV fundamental analysis

No fundamental analysis for Oxurion NV yet.

Oxurion NV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oxurion NV

Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Full company profile